<DOC>
	<DOCNO>NCT02970331</DOCNO>
	<brief_summary>A multi-center , open-label study evaluate safety/tolerability pharmacodynamics well pharmacokinetic profile ( sub-population analysis ) , 50 evaluable adolescent 12 &lt; 17 year age .</brief_summary>
	<brief_title>A Phase 2 , Multicenter , Open-label Study Assess Safety , Tolerability , Pharmacokinetics Pharmacodynamics Pefcalcitol Ointment , 0.005 % , Applied Topically Twice Daily ( BID ) 8 Weeks Adolescent Subjects 12 &lt; 17 Years Age With Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>male female 12 &lt; 17 year age Have confirm diagnosis plaque psoriasis Negative pregnancy test Group 1 : Have plaque psoriasis IGA score ≥ 2 ( mild ) , least one lesion ) 20 % Body Surface Area ( BSA ) involvement include psoriasis face scalp Group 2 : Have plaque psoriasis IGA score ≥ 2 ( mild ) , plaque psoriasis involve least 10 % 20 % Body Surface Area ( BSA ) include psoriasis face scalp know allergy intolerance study drug vitamin D3 analogs component history active generalized guttate , pustular erythrodermic exfoliative psoriasis history presence contact dermatitis induce topical medicine serious skin condition well control Use topical treatment know beneficial effect psoriasis Use phototherapy , oral corticosteroid , oral retinoid , oral immunosuppressive/immunomodulative drug , cytostatics , cyclosporine methotrexate within 30 day prior first dose study drug Use approve biologics psoriasis within 30 day 5 halflives biologic first dose study drug Are treated medication know worsen psoriasis Are take oral vitamin D Are take medication affect calcium metabolism ; Subjects average three ( 3 ) QTcF measurement &gt; 450 millisecond show ECG ( Group 2 ) ; Have clinically significant abnormal calcium homeostasis parameter Visit 1 ; Have clinically significant liver renal dysfunction Have clinically significant laboratory abnormality , comorbidities psychiatric condition would place subject increase risk would confound primary secondary objective study ; Use investigational drug biologics and/or participate clinical trial within last 60 day day first dose study drug take part nonmedication study , would interfere study compliance outcome assessment ; Are pregnant lactate female ; Have know history congenital acquire immunodeficiency .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>